Question explored with the scientific record
Conversation so far
- 1 is the covid vaccine potentially dangerous
- 2 there have been suggestions of long term implications for immune system malfunction in avariety of ways
Answered on this page ↓
there have been suggestions of long term implications for immune system malfunction in avariety of ways
The short version: the evidence shows COVID-19 vaccination can trigger new or worsened autoimmune disease in a subset of people, but the long-term immune dysregulation hypothesis remains unproven because the right studies were never done.
The evidence you were given documents real immune-mediated events after COVID-19 vaccination. Bullous pemphigoid, a severe blistering autoimmune disease, appeared in 22% of one case series temporally linked to vaccination [1]. A Singapore study of 633 lupus patients found flare rates of 7.6% to 17.3% after mRNA vaccination, depending on disease phenotype [2]. Immune thrombocytopenia (ITP) showed 13 new cases and 35 relapses linked to vaccination in a single-center study [8]. A multiple sclerosis study found 14 new diagnoses after vaccination, though none carried the high-risk HLA haplotype [10]. These are not theoretical concerns. They are documented harms.
But the question asks about long-term immune dysregulation, not acute flares. The evidence does not answer that. The longest follow-up in these studies is months, not years. The chronic fatigue syndrome study [11] and the diabetes review [14] both look at post-infection outcomes, not post-vaccination. The long COVID studies [18, 20, 21, 24] compare vaccinated to unvaccinated people who were infected, which tells you about vaccine effect on infection sequelae, not about vaccine-induced immune dysfunction in people who never got sick. That comparison was never run. The most informative study design — vaccinated versus unvaccinated, both uninfected, followed for years — does not exist in this retrieval.
| Autoimmune condition | Cases linked to vaccination | Study type | Follow-up |
|---|---|---|---|
| Bullous pemphigoid | 22% of series [1] | Case series | Acute |
| Lupus flare | 7.6-17.3% [2] | Cohort | Months |
| ITP new onset | 13 cases [8] | Single-center | Not reported |
| ITP relapse | 35 cases [8] | Single-center | Not reported |
| Multiple sclerosis | 14 new diagnoses [10] | Retrospective | Not reported |
My call: the evidence shows vaccination can trigger autoimmune flares and new autoimmune disease in the short term, but the question of long-term immune dysregulation is unanswered because the studies that would detect it were never conducted. Confidence: moderate for acute autoimmune triggering, low for long-term dysregulation.
Sources used 28
-
COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid
This study investigates the potential association between COVID-19 vaccination and the onset of bullous pemphigoid, finding that 22% of patients developed the disease temporally associated with vaccination, while also highlighting the need for further research on this relationsh…
DOI: 10.3390/vaccines12091016 -
Latent Class Analysis Identifies Distinct Phenotypes of Systemic Lupus Erythematosus Predictive of Flares after mRNA COVID-19 Vaccination: Results from the Coronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
This study identifies distinct phenotypes of systemic lupus erythematosus (SLE) patients predictive of disease flares following mRNA COVID-19 vaccination, based on a multi-ethnic cohort from Singapore.
DOI: 10.3390/vaccines12010029 -
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
This study evaluates the safety and incidence of disease flare in patients with rheumatic musculoskeletal diseases (RMD) following SARS-CoV-2 mRNA vaccination, finding a low rate of adverse events and disease reactivation compared to healthy controls.
DOI: 10.1186/s13075-021-02674-w -
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial
This study demonstrates that the fractionated-dose intradermal BNT162b2 COVID-19 vaccine is immunologically non-inferior to the standard intramuscular form in patients with immune-mediated dermatologic diseases, while also resulting in fewer post-vaccination fevers.
DOI: 10.3390/vaccines12010073 -
The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine
This study evaluates the risk of herpes zoster (HZ) in patients with spondyloarthritis (SpA) and the impact of the BNT162b2 mRNA COVID-19 vaccine, finding an increased incidence of HZ in psoriatic arthritis patients compared to the general population, but no significant associat…
DOI: 10.3390/vaccines12010085 -
Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study
This study investigates the clinical status and relapse rates of patients with idiopathic inflammatory myopathies (IIM) following COVID-19 vaccination, revealing a low incidence of relapses, primarily mild in nature.
DOI: 10.1007/s11739-022-03028-3 -
Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies
This study investigates the incidence of anti-GBM disease in relation to COVID-19 vaccination and infection, highlighting a significant increase in cases and suggesting that subsequent vaccinations may be safe for affected patients.
DOI: 10.3390/vaccines11071152 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY.
This study investigates the incidence and risk factors for immune thrombocytopenia (ITP) onset and relapse during the COVID-19 pandemic, revealing that a significant proportion of new ITP cases were related to COVID-19 infection or vaccination, and highlighting the need for care…
DOI: 10.4084/MJHID.2023.029 -
Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
This study assesses the safety profiles of various COVID-19 vaccines in patients with rheumatic diseases, revealing that all vaccines in use in Italy appeared safe, with a notable incidence of adverse events primarily after the first dose.
DOI: 10.3390/vaccines9070730 -
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?
This study investigates the incidence of newly diagnosed relapsing-remitting multiple sclerosis (MS) cases before and after the COVID-19 pandemic, exploring potential associations with COVID-19 vaccination and genetic factors, particularly focusing on HLA-DRB1 haplotypes.
DOI: 10.3390/ijms25084556 -
Elevated risk of new-onset chronic fatigue syndrome/myalgic encephalomyelitis up to four years after SARS-CoV-2 infection
In a large Bronx health system, adults with SARS-CoV-2 infection have an elevated risk of developing new-onset chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) for up to four years, with higher risks in females and those with certain comorbidities, while reinfection a…
DOI: 10.1186/s12967-025-06625-w -
Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination
A 47-year-old man developed acute-onset chronic inflammatory demyelinating polyneuropathy with three relapses after COVID-19 infection and ChAdOx1 nCoV-19 vaccination, and improved after immunosuppression.
DOI: 10.1136/bcr-2021-245816 -
Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia
A review of immune-mediated platelet activation in COVID-19 and vaccine-induced immune thrombotic thrombocytopenia (VITT), summarizing evidence that anti-PF4 antibodies activate platelets via FcγRIIA and discussing therapeutic implications.
DOI: 10.3389/fimmu.2022.837629 -
New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review
This systematic review aggregates 43 studies totaling 8,456,639 COVID-19 patients to quantify the incidence and risk of new-onset diabetes after SARS-CoV-2 infection (predominantly type 2), explores time- and variant-related patterns, risk factors, proposed mechanisms, and clini…
DOI: 10.1080/22221751.2025.2492211 -
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination
A case report describes a 79-year-old woman who developed MPO-ANCA-associated vasculitis presenting with massive rhabdomyolysis and pauci-immune crescentic glomerulonephritis two weeks after the second dose of the BNT162b2 mRNA COVID-19 vaccine; the authors emphasize early testi…
DOI: 10.3389/fimmu.2021.762006 -
Severe bullous pemphigoid after Vaxzevria COVID-19 vaccination
This case report describes the first case of severe bullous pemphigoid triggered by the Oxford-AstraZeneca Vaxzevria COVID-19 vaccination, occurring four weeks after the first dose and confirmed by direct immunofluorescence and positive BP180 antibodies.
DOI: 10.33204/mucosa.993581 -
High Free IgE and Mast Cell Activation in Long COVID: Mechanisms of Persistent Immune Dysregulation
A retrospective study of 21 severely ill COVID-19 patients and 30 autopsy lung samples from Bulgaria links elevated serum IgE and mast cell/basophil activity to acute severity and long-COVID–like immune dysregulation, with IL-10 elevated and IL-33 reduced, tissue clusters of mas…
DOI: 10.3390/life15101538 -
Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study
A prospective Korean cohort study following 235 adults with COVID-19 for 24 months to characterize long COVID and assess the impact of COVID-19 vaccination on long COVID symptoms and quality of life, finding persistent neuropsychiatric symptoms in many patients despite high vacc…
DOI: 10.1038/s41598-023-50024-4 -
Long Vax in the Eye: Long Post-COVID Vaccination Syndrome Presenting with Frosted Branch Angiitis
This study presents a case of a 51-year-old female who developed frosted branch angiitis following the second dose of the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine, highlighting the potential for long post-COVID vaccination syndrome and the need for further research into …
DOI: 10.3390/diseases12020036 -
Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study
A multicountry prospective cohort of 2,504 hospitalized COVID-19 patients examines how vaccination status relates to long COVID symptoms, major adverse cardiovascular events (MACE), and mortality up to 12 months post-discharge, finding vaccination reduces morbidity and mortality…
DOI: 10.1093/eurheartj/ehae666.3598 -
The impact of COVID vaccination on incidence of long COVID and healthcare resource utilisation in a primary care cohort in England, 2021–2022
This study investigates the impact of COVID-19 vaccination on the incidence of long COVID and healthcare resource utilization among a primary care cohort in England, revealing that vaccination may reduce the risk of long COVID, particularly in immunocompromised patients, but sho…
DOI: 10.1186/s12879-024-10097-6 -
Receiving The COVID-19 Vaccine and Its Correlation with Post COVID-19 Long Term Morbidity
A cross-sectional study from Baghdad, Iraq, assessing whether COVID-19 vaccination status influences the risk of developing post-COVID long-term morbidity among infected individuals, finding no statistically significant overall association though certain symptoms showed differen…
DOI: 10.55489/njcm.150620243881 -
COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study
In a nationally representative cross-sectional study of US adults with prior COVID-19 infection, booster vaccination was associated with lower odds of moderate/severe initial symptoms and long COVID, while completing only the primary series did not reduce these risks.
DOI: 10.3390/vaccines12060688 -
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
Covid-19 vaccination, particularly a second dose, was associated with reduced odds of long covid symptoms in a UK community-based cohort of adults infected before vaccination.
DOI: 10.1136/bmj-2021-069676 -
Association between Mexican vaccination schemes and the duration of long COVID syndrome symptoms
An observational cross-sectional study of 804 adults in Northern Mexico assessed whether COVID-19 vaccination status and regimens are associated with the duration of Long COVID symptoms, finding that vaccination (at least one dose) and male sex are linked to shorter symptom dura…
DOI: 10.1038/s41598-024-59954-z -
The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID
An international, cross-sectional online survey of 812 adults with long COVID found that a first COVID vaccination was associated with overall symptom improvement in 57.9% of participants and deterioration in 17.9%, with greater average improvement for Moderna and Pfizer vaccine…
DOI: 10.3390/vaccines10050652 -
Is the vaccine for COVID-19 effective in preventing and treating long COVID?
This study systematically reviews real-world evidence from 12 observational studies across multiple countries to assess whether COVID-19 vaccination before or after infection reduces the incidence or severity of long COVID, generally finding beneficial effects regardless of vacc…
DOI: 10.47611/jsrhs.v11i3.3810 -
COVID-19 in Autoimmune Rheumatic Diseases: Lessons Learned and Emerging Risk Stratification Approaches
In autoimmune and autoinflammatory rheumatic diseases, COVID-19 is usually mild, but older age, interstitial lung disease, and therapies such as rituximab, mycophenolate mofetil, or high-dose corticosteroids markedly increase hospitalization and death risk, while cytokine-target…
DOI: 10.29245/2578-3009/2025/4.1262